Accueil > Actualités > Communiqués


Mardi 07 Avr 2009 à 16:01

Assemblée générale annuelle des actionnaires

- Les actionnaires approuvent les résultats de 2008 : chiffre d'affaires consolidé 689,6 millions d'E (+ 9,7 %), résultat d'exploitation (EBIT) 144,7 millions d'E (+ 10,1 %), résultat net 100,4 millions d'E (+ 18,3 %).

- Dividende à verser 0,25 E par action, soit une augmentation de 16,3 % par rapport au dividende versé l'année dernière. Dividende total 49,3 millions d'E.

- Renouvellement de l'autorisation de racheter les actions de Recordati.

Milan, 7 avril 2009 - L'assemblée générale annuelle des actionnaires de Recordati s'est tenue aujourd'hui.

Assemblée générale annuelle des actionnaires

L'assemblée générale annuelle des actionnaires de Recordati a approuvé les comptes financiers 2008 de la société qui ont été préparés selon les normes IAS/IFRS. In addition, the group's consolidated statements, which were also prepared according to IAS/IFRS, were presented. The tables attached contain a summary of the 2008 financial statements. As previously announced on 3 March 2009 revenues are E 689.6 million (+9.7%), operating income (EBIT) is E 144.7 million (+ 10.1%), and net income is E 100.4 million (+ 18.3%). International sales account for 70.2% of total sales.

As proposed by the Board of Directors, the shareholders approved a dividend of E 0.25 per share (E 0.215 the preceding year) to be paid to the shares outstanding as from 23 April 2009 (trading ex-dividend as from 20 April 2009), excluding those shares in treasury stock. The overall amount of the dividend to be paid is E 49.3 million compared to E 42.2 million paid the preceding year, an increase of 16.7%.

Furthermore, the Shareholders' Meeting renewed the buy-back authorization granted by the Shareholders on 11 April 2008 for a period ending with the approval of the 2009 accounts. This authorization is granted for the following purposes: use shares for equity acquisitions or as consideration for strategic agreements; allow the company to invest in its own shares; and service current and future stock OPTION plans with existing rather than new shares. The company is allowed to purchase up to 20,000,000 Recordati existing ordinary (common) shares, which includes those shares held in Treasury stock at any given time, for a maximum cash outlay of E 120,000,000. The purchase price must be at least equal to the shares' nominal value (E 0.125) and must not exceed the average official Stock Exchange price recorded over the 5 trading days prior to the transaction, plus 5%. Possible purchases must comply with the Issuers' Rules and Regulations. No shares were purchased under the authorization granted by the Shareholders' Meeting of 11 April 2008. The company currently has 11,472,355 shares in Treasury stock which amounts to 5.5021% of the current share capital.

First quarter 2009

Group sales in the first quarter 2009 are substantially in line with our expectations for the full year which are to achieve revenues of around E 750 million, operating income of around E 155 million and net income of around E 105 million.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,900, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of over 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was E 689.6 million, operating income was E 144.7 million and net income was E 100.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke


e-mail: inver@recordati.it

Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)02 62694736

e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.


Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of E)

Change %  
REVENUE   689,634   628,435   9.7  
Cost of sales   (222,196)   (206,350)   7.7  
GROSS PROFIT   467,438   422,085   10.7  
Selling expenses   (214,245)   (202,043)   6.0  
Research and development expenses   (58,860)   (49,122)   19.8  
General & administrative expenses   (39,372)   (33,927)   16.0  
Other income (expenses), net   (10,231)   (5,497)   n.s.  
OPERATING INCOME   144,730   131,496   10.1  
Financial income (expenses), net   (6,584)   (4,071)   61.7  
PRE-TAX INCOME   138,146   127,425   8.4  
Provision for income taxes   (37,717)   (42,560)   (11.4)  
NET INCOME   100,429   84,865   18.3  
Attributable to:        
Equity holders of the parent   100,424   84,865   18.3  
Minority interests   5   0   n.s.  
Change %  
Basic   E 0.511   E 0.427   19.7  
Diluted   E 0.501   E 0.417   20.1  

Earnings per share (EPS) are based on average shares outstanding during each year, 196,667,301 in 2008 and 198,557,743 in 2007, net of average treasury stock which amounted to 11,472,355 in 2008 and 8,495,866 in 2007. Diluted earnings per share is calculated taking into account new shares authorized but not yet issued.


Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of E)

Property, plant and equipment   57,969   68,006    
Intangible assets   92,635   90,521    
Goodwill   289,822   239,903   *  
Equity investments   7,532   3,115    
Non-current receivables   5,199   6,661   *  
Deferred tax assets   22,650   21,324   *  
TOTAL NON-CURRENT ASSETS   475,807   429.530    
Inventories   83,087   74,737    
Trade receivables   137,015   134,454    
Other receivables   22,741   30,284   *  
Other current assets   2,346   3,247    
Short-term financial investments, cash and cash equivalents   94,951   89,382    
TOTAL CURRENT ASSETS   340,140   332,104    
TOTAL ASSETS   815,947   761,634    
Share capital   26,063   25,981    
Capital in excess of par value   81,320   78,952    
Treasury stock   (59,103)   (59,103)    
Hedging reserve   (2,532)   (113)    
Translation reserve   (7,096)   (3,384)    
Other reserves   25,733   25,529    
Retained earnings   280,920   237,876    
Net income for the year   100,424   84,865    
GROUP SHAREHOLDERS' EQUITY   445,729   390,603    
Minority interest   13   8    
SHAREHOLDERS' EQUITY   445,742   390,611    
Loans due after one year   81,409   77,250    
Employees' termination pay   19,624   20,431    
Deferred tax liabilities   7,399   9,681   *  
Other non-current liabilities   3,189   5,965   *  
TOTAL NON-CURRENT LIABILITIES   111.621   113,327    
Trade payables   88,598   80,343    
Other payables   47,147   41,765   *  
Tax liabilities   10,278   15,762    
Other current liabilities   385   346    
Provisions   15,094   10,076    
Fair value of hedging derivatives (cash flow hedge)   2,532   113    
Fair value of hedging derivatives (fair value hedge)   1,505   7,556    
Loans due within one year   2,201   2,939    
Bank overdrafts and short term loans   90,844   98,796    
TOTAL CURRENT LIABILITIES   258,584   257,696    
TOTAL EQUITY AND LIABILITIES   815,947   761,634    

* Restated to include final Orphan Europe goodwill allocation.


Summary of results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of E)

Var. %  
Net revenue   248,872   259,745   (4.2)  
Operating income   44,701   60,473   (26.1)  
Pre-tax income   67,097   68,050   (1.4)  
Net income   52,945   50,376   5.1  
Non-current assets   356,054   301,032  
Current assets   201,809   221,743  
Total assets   557,863   522,775  
Shareholders' equity   273,161   261,842  
Non-current liabilities   95,372   92,116  
Current liabilities   189,330   168,817  
Total liabilities and Shareholders' equity   557,863   522,775  


The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.

Copyright Hugin

Ce communiqué de presse est diffusé par Hugin. L'émetteur est seul responsable du contenu de ce communiqué.


Partager sur Facebook
Article Précédent :
GROUPE Pose de la première pierre...
Article Suivant :
Chiffre d'affaires du premier...

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 

Les autres actualités

Retour vers 'Communiqués' »

Mots-clés :    Ifrs   Income   Sales   Dividend   Share   Outstanding   Trading   Those   Purchase   Price   Must   European   Dedicated   Growing   Within   Contained   Looking   Assumptions   Standards   Thousands   Minority   Earnings   Diluted   Assets   Goodwill   Short   Hedging   Loans   Hedge  
Sociétés citées dans cette news : Option   FINANCIAL  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?